Major bleeding with old and novel oral anticoagulants: How to manage it

In the last decade, the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) in clinical practice has changed the therapeutic landscape in the prevention of thromboembolic events. Although NOACs compared to vitamin K antagonists (VKAs) have demonstrated a similar or slightly lower rate of major bleeding and a lower rate of intracranial or fatal bleeding, hemorrhaging still represents the main adverse effect of anticoagulant treatment. This review reports data on the rates of major bleeding with old and new oral anticoagulants.

Source: International Journal of Cardiology - May 23, 2018 Category: Cardiology Authors: Stefania Angela Di Fusco, Fabiana Luc à, Manuela Benvenuto, Annamaria Iorio, Damiana Fiscella, Fabrizio D'Ascenzo, Andrea Madeo, Furio Colivicchi, Andrea Di Lenarda, Michele Massimo Gulizia Source Type: research